$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

$eltp Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000114420418058784 Filed on November 09, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2018 Q1
Revenue	$2.694M	$1.363M	$1.597M
YoY Change	6.27%	-16.05%	18.3%
Cost Of Revenue	$1.771M	$542.6K	$461.0K
YoY Change	24.73%	-11.77%	168.02%
Gross Profit	$922.8K	$820.5K	$1.136M
YoY Change	-17.23%	-18.65%	-3.57%
Gross Profit Margin	34.26%	60.2%	71.13%
Selling, General & Admin	$784.7K	$651.5K
YoY Change
% of Gross Profit	85.03%	79.4%
Research & Development	$2.454M	$2.455M
YoY Change	-2.4%	7.39%
% of Gross Profit	265.93%	299.27%
Depreciation & Amortization	$411.2K	$313.4K	$290.0K
YoY Change	44.02%	38.64%	38.1%
% of Gross Profit	44.55%	38.2%	25.53%
Operating Expenses	$3.560M	$3.473M	$3.759M
YoY Change	12.12%	10.67%	-13.94%
Operating Profit	-$2.637M	-$2.653M	-$2.623M
YoY Change	28.02%	24.56%	-17.77%
Interest Expense	$292.8K	$106.0K
YoY Change	216.7%	28.42%
% of Operating Profit
Other Income/Expense, Net		$69.44K	-$203.0K
YoY Change		-98.24%	-5175.0%
Pretax Income	-$2.344M	-$2.584M
YoY Change	52.08%	-242.33%
Income Tax	$0.00	$0.00	$3.000K
% Of Pretax Income
Net Earnings	-$2.344M	-$2.584M	-$2.829M
YoY Change	378.43%	-242.34%	-11.21%
Net Earnings / Revenue	-87.02%	-189.54%	-177.14%
Basic Earnings Per Share		$0.00	$0.00
Diluted Earnings Per Share	-$2.861K	$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	819.5M shares	812.3M shares
Diluted Shares Outstanding		812.3M shares

Balance Sheet

Concept	2018 Q4	2018 Q3	2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.681M	$4.705M	$7.180M
YoY Change	-49.16%	-37.76%	-32.2%
Cash & Equivalents		$4.705M	$7.179M
Short-Term Investments
Other Short-Term Assets	$897.8K	$170.8K	$950.0K
YoY Change	-15.3%	-34.3%	102.13%
Inventory	$4.192M	$4.486M	$4.898M
Prepaid Expenses
Receivables	$660.4K	$1.016M	$675.9K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$9.431M	$10.38M	$13.70M
YoY Change	-36.1%	-28.97%	-25.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.755M	$8.755M	$8.994M
YoY Change	-4.13%	-5.55%	-0.51%
Goodwill
YoY Change
Intangibles		$7.713M	$7.713M
YoY Change			20.16%
Long-Term Investments	$81.62K	$80.58K	$80.00K
YoY Change	2.03%	61.16%	60.0%
Other Assets	$396.1K	$475.0K	$473.5K
YoY Change	1.57%	21.79%	21.41%
Total Long-Term Assets	$16.95M	$16.94M	$17.18M
YoY Change	-2.13%	-2.62%	8.04%
TOTAL ASSETS
Total Short-Term Assets	$9.431M	$10.38M	$13.70M
Total Long-Term Assets	$16.95M	$16.94M	$17.18M
Total Assets	$26.38M	$27.32M	$30.88M
YoY Change	-17.76%	-14.65%	-9.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.309M	$1.141M	$1.658M
YoY Change	59.89%	32.69%	57.95%
Accrued Expenses	$3.031M	$2.662M	$1.789M
YoY Change	69.77%	98.69%	125.08%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$586.6K	$547.6K	$650.0K
YoY Change	17.31%	24.45%	32.65%
Total Short-Term Liabilities	$6.940M	$5.364M	$5.115M
YoY Change	46.42%	46.97%	52.92%
LONG-TERM LIABILITIES
Long-Term Debt	$3.399M	$3.252M	$3.330M
YoY Change	1.77%	-2.06%	54.17%
Other Long-Term Liabilities	$2.399M	$44.30K	$41.14K
YoY Change	5959.14%	-99.11%	29.51%
Total Long-Term Liabilities	$5.798M	$6.283M	$7.292M
YoY Change	14545.19%	-24.03%	22853.7%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.940M	$5.364M	$5.115M
Total Long-Term Liabilities	$5.798M	$6.283M	$7.292M
Total Liabilities	$12.74M	$11.65M	$12.41M
YoY Change	4.58%	-2.29%	267.45%
SHAREHOLDERS EQUITY
Retained Earnings		-$146.8M	-$142.5M
YoY Change
Common Stock		$148.9M	$147.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)		$306.8K	$306.8K
YoY Change
Treasury Stock Shares		100.0K shares	100.0K shares
Shareholders Equity	$13.64M	$1.770M	$4.572M
YoY Change
Total Liabilities & Shareholders Equity	$26.38M	$27.32M	$30.88M
YoY Change	-17.75%	-14.65%	-9.99%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2018 Q1
OPERATING ACTIVITIES
Net Income	-$2.344M	-$2.584M	-$2.829M
YoY Change	378.43%	-242.34%	-11.21%
Depreciation, Depletion And Amortization	$411.2K	$313.4K	$290.0K
YoY Change	44.02%	38.64%	38.1%
Cash From Operating Activities	-$1.268M	-$1.679M	-$1.010M
YoY Change	164.17%	-24.72%	-75.18%
INVESTING ACTIVITIES
Capital Expenditures	-$19.13K	$180.0K	$110.0K
YoY Change	-123.91%	-250.0%	-137.93%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change
Cash From Investing Activities	-$19.13K	$180.0K	$100.0K
YoY Change	-123.91%	-250.0%	-134.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	264.3K	567.5K	850.0K
YoY Change	230.34%	71.97%	-49.4%
NET CHANGE
Cash From Operating Activities	-1.268M	-1.679M	-1.010M
Cash From Investing Activities	-19.13K	180.0K	100.0K
Cash From Financing Activities	264.3K	567.5K	850.0K
Net Change In Cash	-1.023M	-931.2K	-60.00K
YoY Change	219.65%	-53.9%	-97.76%
FREE CASH FLOW
Cash From Operating Activities	-$1.268M	-$1.679M	-$1.010M
Capital Expenditures	-$19.13K	$180.0K	$110.0K
Free Cash Flow	-$1.249M	-$1.859M	-$1.120M
YoY Change	123.02%	-11.91%	-70.37%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Registrant Name EntityRegistrantName	ELITE PHARMACEUTICALS INC /NV/
	dei	Entity Central Index Key EntityCentralIndexKey	0001053369
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Trading Symbol TradingSymbol	ELTP
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	819489751	shares
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Small Business EntitySmallBusiness	false
	us-gaap	Revenues Revenues	3530747	USD
	us-gaap	Revenues Revenues	3326351	USD
	us-gaap	Cost Of Revenue CostOfRevenue	2118950	USD
	us-gaap	Cost Of Revenue CostOfRevenue	1630001	USD
	us-gaap	Gross Profit GrossProfit	1411797	USD
	us-gaap	Gross Profit GrossProfit	1696350	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3782094	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4108504	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1497749	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1453034	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	73094	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	170758	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	570226	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	335196	USD
	us-gaap	Operating Expenses OperatingExpenses	5923163	USD
	us-gaap	Operating Expenses OperatingExpenses	6067492	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4511366	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4371142	USD
	us-gaap	Interest Expense InterestExpense	189140	USD
	us-gaap	Interest Expense InterestExpense	153272	USD
	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	426371	USD
	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	4162436	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2837	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	8401	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	240068	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4017565	USD
CY2018Q3	us-gaap	Revenues Revenues	1363049	USD
CY2017Q3	us-gaap	Revenues Revenues	1623581	USD
CY2018Q3	us-gaap	Cost Of Revenue CostOfRevenue	542551	USD
CY2017Q3	us-gaap	Cost Of Revenue CostOfRevenue	614941	USD
CY2018Q3	us-gaap	Gross Profit GrossProfit	820498	USD
CY2017Q3	us-gaap	Gross Profit GrossProfit	1008640	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2455466	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2286514	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	614937	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	594073	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	36545	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	73397	USD
CY2018Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	366522	USD
CY2017Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	184527	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	3473470	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	3138511	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2652972	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2129871	USD
CY2018Q3	us-gaap	Interest Expense InterestExpense	106002	USD
CY2017Q3	us-gaap	Interest Expense InterestExpense	82541	USD
CY2018Q3	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	173860	USD
CY2017Q3	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	4023176	USD
CY2018Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	1582	USD
CY2017Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	4419	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	69440	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3945054	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1396284	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	20321	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	73094	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1396280	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	955691	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	181908	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	49957	USD
	us-gaap	Interest Paid Net InterestPaidNet	24044	USD
	us-gaap	Interest Paid Net InterestPaidNet	38215	USD
	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	375194	USD
	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	251504	USD
	us-gaap	Notes Issued1 NotesIssued1	0	USD
	us-gaap	Notes Issued1 NotesIssued1	1200000	USD
	eltp	Commitment Shares Issued CommitmentSharesIssued	20321	USD
	eltp	Commitment Shares Issued CommitmentSharesIssued	939318	USD
	eltp	Retirement Of Common Shares Pursuant To Issuance Of Series J Convertible Preferred Shares RetirementOfCommonSharesPursuantToIssuanceOfSeriesJConvertiblePreferredShares	0	USD
	eltp	Retirement Of Common Shares Pursuant To Issuance Of Series J Convertible Preferred Shares RetirementOfCommonSharesPursuantToIssuanceOfSeriesJConvertiblePreferredShares	20378631	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4271298	USD
	us-gaap	Net Income Loss NetIncomeLoss	-353577	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	530652	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	412719	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-426371	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4162436	USD
	eltp	Accrued Compensation Non Cash AccruedCompensationNonCash	1191339	USD
	eltp	Accrued Compensation Non Cash AccruedCompensationNonCash	923500	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	73094	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	170758	USD
	eltp	Noncash Rent Expense And Lease Accretion NoncashRentExpenseAndLeaseAccretion	3151	USD
	eltp	Noncash Rent Expense And Lease Accretion NoncashRentExpenseAndLeaseAccretion	5205	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	339967	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	151219	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-412059	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-707134	USD
	eltp	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	-779835	USD
	eltp	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	-208223	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-834553	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-571135	USD
	eltp	Increase Decrease In Deferred Revenue And Customer Deposits IncreaseDecreaseInDeferredRevenueAndCustomerDeposits	-506666	USD
	eltp	Increase Decrease In Deferred Revenue And Customer Deposits IncreaseDecreaseInDeferredRevenueAndCustomerDeposits	-506667	USD
	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	0	USD
	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	386564	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	75274	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7570803	USD
CY2017Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10983774	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5099591	USD
CY2017Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7946651	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2471212	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3037123	USD
	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	-388767	USD
	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	-260432	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3388725	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3317495	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-461838	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	917513	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	742210	USD
CY2018Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	394402	USD
CY2018Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	391566	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	260	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	807677777	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	800772162	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	807677777	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	807141399	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.15
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.15
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y1M6D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y6M
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	60000	USD
CY2018Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	60000	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	6369237	shares
CY2018Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	17777881	USD
CY2018Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	17402687	USD
CY2018Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9022541	USD
CY2018Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8408979	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8755340	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8993708	USD
CY2018Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	6419091	USD
CY2018	eltp	Intangible Assets Excluding Goodwill Acquired IntangibleAssetsExcludingGoodwillAcquired	1293910	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	58720	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	40781	USD
CY2018Q3	us-gaap	Deferred Revenue DeferredRevenue	1758890	USD
CY2018Q1	us-gaap	Deferred Revenue DeferredRevenue	2265556	USD
CY2018Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1013333	USD
CY2018Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1013333	USD
CY2018Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	745557	USD
CY2018Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1252223	USD
CY2017Q2	eltp	Fair Value Inputs Preferred Stock Trials FairValueInputsPreferredStockTrials	200000	shares
CY2018Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50.000	shares
CY2018Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	24.0344	shares
CY2018Q3	eltp	Convertible Preferred Stock Par Value Per Share ConvertiblePreferredStockParValuePerShare	0.01
CY2018Q3	eltp	Convertible Preferred Stock Stated Value ConvertiblePreferredStockStatedValue	1000000	USD
CY2018Q3	eltp	Preferred Stock Conversion Price Per Share PreferredStockConversionPricePerShare	0.1521
CY2018Q3	eltp	Common Shares To Be Issued Upon Conversion CommonSharesToBeIssuedUponConversion	158017321	shares
CY2018Q1	eltp	Warrants Outstanding WarrantsOutstanding	79008661	shares
CY2017Q1	eltp	Warrants Outstanding WarrantsOutstanding	9379219	shares
	eltp	Warrants Granted During Period WarrantsGrantedDuringPeriod	0	shares
CY2018	eltp	Warrants Granted During Period WarrantsGrantedDuringPeriod	79008661	shares
	eltp	Warrant Exercised Forfeitures And Expirations During Period WarrantExercisedForfeituresAndExpirationsDuringPeriod	0	shares
CY2018	eltp	Warrant Exercised Forfeitures And Expirations During Period WarrantExercisedForfeituresAndExpirationsDuringPeriod	9379219	shares
CY2018Q3	eltp	Warrants Outstanding WarrantsOutstanding	79008661	shares
CY2018Q1	eltp	Warrants Outstanding Weighted Average Exercise Price WarrantsOutstandingWeightedAverageExercisePrice	0.1521
CY2017Q1	eltp	Warrants Outstanding Weighted Average Exercise Price WarrantsOutstandingWeightedAverageExercisePrice	0.0625
	eltp	Warrants Granted During Period Weighted Average Exercise Price WarrantsGrantedDuringPeriodWeightedAverageExercisePrice	0
CY2018	eltp	Warrants Granted During Period Weighted Average Exercise Price WarrantsGrantedDuringPeriodWeightedAverageExercisePrice	0.1521
CY2018Q3	eltp	Warrants Outstanding Weighted Average Exercise Price WarrantsOutstandingWeightedAverageExercisePrice	0.1521
	eltp	Warrant Exercised Forfeitures And Expiration Weighted Average Exercise Price WarrantExercisedForfeituresAndExpirationWeightedAverageExercisePrice	0
CY2018	eltp	Warrant Exercised Forfeitures And Expiration Weighted Average Exercise Price WarrantExercisedForfeituresAndExpirationWeightedAverageExercisePrice	0.0625
CY2017Q2	eltp	Warrant Expiration Period WarrantExpirationPeriod	P10Y
CY2018Q1	eltp	Derivative Liability Warrants DerivativeLiabilityWarrants	2667871	USD
	eltp	Derivative Liability Warrants Change In Fair Value Of Warrant Liability DerivativeLiabilityWarrantsChangeInFairValueOfWarrantLiability	426371	USD
CY2018Q3	eltp	Derivative Liability Warrants DerivativeLiabilityWarrants	2241500	USD
CY2018Q3	eltp	Common Stock Traded Percent CommonStockTradedPercent	0.3	pure
CY2018Q3	eltp	Common Stock Weighted Average Price Percent CommonStockWeightedAveragePricePercent	0.97	pure
	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	902500	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6618000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	403000	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6215000	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5628334	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y2M12D
CY2018Q3	eltp	Price Difference Between Exercise Price And Quoted Price PriceDifferenceBetweenExercisePriceAndQuotedPrice	0.09
CY2018Q1	eltp	Price Difference Between Exercise Price And Quoted Price PriceDifferenceBetweenExercisePriceAndQuotedPrice	0.10
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.16
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.30
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4705189	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7179237	USD
CY2018Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1015846	USD
CY2018Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	675879	USD
CY2018Q3	us-gaap	Liabilities Liabilities	11647513	USD
CY2018Q1	us-gaap	Liabilities Liabilities	12407096	USD
CY2018Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	13903960	USD
CY2018Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	13903960	USD
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	816965	USD
CY2018Q1	us-gaap	Common Stock Value CommonStockValue	802629	USD
CY2018Q3	us-gaap	Inventory Net InventoryNet	4485942	USD
CY2018Q1	us-gaap	Inventory Net InventoryNet	4898001	USD
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	170806	USD
CY2018Q3	us-gaap	Assets Assets	27321101	USD
CY2018Q1	us-gaap	Assets Assets	30882608	USD
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1141109	USD
CY2018Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1658137	USD
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	949284	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	10377783	USD
CY2018Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2662385	USD
CY2018Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1788571	USD
CY2018Q3	us-gaap	Secured Debt Current SecuredDebtCurrent	80822	USD
CY2018Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	75822	USD
CY2018Q3	us-gaap	Loans Payable Current LoansPayableCurrent	466778	USD
CY2018Q1	us-gaap	Loans Payable Current LoansPayableCurrent	578841	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5364427	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5114704	USD
CY2018Q3	us-gaap	Secured Long Term Debt SecuredLongTermDebt	1420224	USD
CY2018Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	1508134	USD
CY2018Q3	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	1200000	USD
CY2018Q1	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	1200000	USD
CY2018Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable	631510	USD
CY2018Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	623020	USD
CY2018Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	44295	USD
CY2018Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	41144	USD
CY2018Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	6283086	USD
CY2018Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	7292392	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	13702401	USD
CY2018Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	7713001	USD
CY2018Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	7713001	USD
CY2018Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	394402	USD
CY2018Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	391566	USD
CY2018Q3	us-gaap	Security Deposit SecurityDeposit	80575	USD
CY2018Q1	us-gaap	Security Deposit SecurityDeposit	81932	USD
CY2018Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	474977	USD
CY2018Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	473498	USD
CY2018Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	148057540	USD
CY2018Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	146602502	USD
CY2018Q3	us-gaap	Treasury Stock Value TreasuryStockValue	306841	USD
CY2018Q1	us-gaap	Treasury Stock Value TreasuryStockValue	306841	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-146798036	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-142526738	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27321101	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30882608	USD
CY2018Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2018Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2018Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9022541	USD
CY2018Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8408979	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	USD
CY2018Q3	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.01
CY2018Q3	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	50	shares
CY2018Q3	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	24.0344	shares
CY2018Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	50	shares
CY2018Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	24.0344	shares
CY2018Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.01
CY2018Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	24.0344	shares
CY2018Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	24.0344	shares
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	995000000	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	816962249	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	816862249	shares
CY2018Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	802626761	shares
CY2018Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	802526761	shares
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	995000000	shares
CY2018Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
CY2018Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	4571552	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	1769628	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	90000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	85000	USD
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;">Reclassifications</div></div></div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; text-indent: 0.5in;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Certain reclassifications have been made to the prior period financial statements to conform to the current period financial statement presentation. These reclassifications had no effect on net earnings or cash flows as previously reported.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1815183	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4271298	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-353577	USD
CY2018Q3	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	0	USD
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2583532	USD
CY2017Q3	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	4023176	USD
	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	0	USD
	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	4162436	USD
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2583532	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2207993	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4271298	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4516013	USD
CY2018Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	812256006	shares
CY2017Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	782424624	shares
CY2018Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2017Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	6369237	shares
CY2018Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	812256006	shares
CY2017Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	788793861	shares
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
	us-gaap	Depreciation Depreciation	613562	USD
	us-gaap	Depreciation Depreciation	410630	USD
	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P0Y
CY2018Q3	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	7713001	USD
	eltp	Intangible Assets Excluding Goodwill Acquired IntangibleAssetsExcludingGoodwillAcquired	0	USD
CY2018	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P0Y
CY2017Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	3544	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	7090	USD
CY2018Q3	us-gaap	Depreciation Depreciation	313395	USD
CY2017Q3	us-gaap	Depreciation Depreciation	226044	USD
CY2018Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	27559	USD
CY2017Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	19022	USD
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 9. COMMITMENTS AND CONTINGENCIES</div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Occasionally, the Company may be involved in claims and legal proceedings arising from the ordinary course of its business. The Company records a provision for a liability when it believes that is both probable that a liability has been incurred, and the amount can be reasonably estimated. If these estimates and assumptions change or prove to be incorrect, it could have a material impact on the Company’s condensed consolidated financial statements. Contingencies are inherently unpredictable, and the assessments of the value can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions.</div></div><div style="background: none; font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="background: rgb(255, 255, 255); font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Operating Leases – 135 Ludlow Ave.</div></div></div></div><div style="background: none; font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="background: rgb(255, 255, 255); font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company entered into an operating lease for a portion of a one-story warehouse, located at 135 Ludlow Avenue, Northvale, New Jersey (the “135 Ludlow Ave. lease”). The 135 Ludlow Ave. lease is for approximately 15,000 square feet of floor space and began on July 1, 2010. During July 2014, the Company modified the 135 Ludlow Ave. lease in which the Company was permitted to occupy the entire 35,000 square feet of floor space in the building (“135 Ludlow Ave. modified lease”).</div></div><div style="background: none; font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="background: rgb(255, 255, 255); font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The 135 Ludlow Ave. modified lease includes an initial term, which expired on December 31, 2016 with two tenant renewal options of five years each, at the sole discretion of the Company. On June 22, 2016, the Company exercised the first of these renewal options, with such option including a term that begins on January 1, 2017 and expires on December 31, 2021.</div></div><div style="background: none; font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="background: rgb(255, 255, 255); font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The 135 Ludlow Ave. property required significant leasehold improvements and qualifications, as a prerequisite, for its intended future use. Manufacturing, packaging, warehousing and regulatory activities are currently conducted at this location.</div></div><div style="background: none; font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="background: rgb(255, 255, 255); font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Rent expense is recorded on the straight-line basis. Rents paid in excess is recognized as deferred rent. Rent expense under the 135 Ludlow Ave. modified lease for the three months ended September 30, 2018 and 2017 was $54,909, and $109,818 for the six months ended September 30, 2018 and 2017. Rent expense is recorded in general and administrative expense in the unaudited condensed consolidated statements of operations. Deferred rent as of September 30, 2018 and March 31, 2018 was $11,902 and $9,705, respectively and recorded as a component of other long-term liabilities.</div></div><div style="background: none; font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="background: rgb(255, 255, 255); font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company has an obligation for the restoration of its leased facility and the removal or dismantlement of certain property and equipment as a result of its business operation in accordance with ASC 410, </div><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Asset Retirement and Environmental Obligations – Asset Retirement Obligations</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">. The Company records the fair value of the asset retirement obligation in the period in which it is incurred. The Company increases, annually, the liability related to this obligation. The liability is accreted to its present value each period and the capitalized cost is depreciated over the useful life of the related asset. Upon settlement of the liability, the Company records either a gain or loss. As of September 30, 2018, and March 31, 2018, the Company had a liability of $32,398 and $31,443, respectively and recorded as a component of other long-term liabilities.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	eltp	Revenues Recognition Milestone Method Milestone RevenuesRecognitionMilestoneMethodMilestone	The milestones, totaling $500k (with $405k already received), consist of amounts due upon the first shipment of each identified product, as follows: Phentermine 37.5mg tablets ($145k), Phentermine 15 & 30mg capsules ($45k), Hydromorphone 8mg ($125k), Naltrexone 50mg ($95k) and the balance of $95k due in relation to the first shipment of generic products which still require marketing authorizations from the FDA, and to which there can be no assurances of such marketing authorizations being granted and accordingly there can be no assurances that the Company will earn and receive these milestone amounts.
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	90390	USD
CY2017Q3	us-gaap	Concentration Risk Percentage1 ConcentrationRiskPercentage1	0.28	pure
CY2018Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2018Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
	eltp	Stock Issued During Period Value Additional Issues StockIssuedDuringPeriodValueAdditionalIssues	20317	USD
CY2018Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	63107	USD
CY2018Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	229204	USD
CY2018Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	112285	USD
CY2018Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	297350	USD
CY2018Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	4310550	USD
CY2018Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	4371447	USD
CY2018Q3	us-gaap	Inventory Gross InventoryGross	4485942	USD
CY2018Q1	us-gaap	Inventory Gross InventoryGross	4898001	USD

Files In Submission

Name	View Source	Status
0001144204-18-058784-index-headers.html	Edgar Link	pending
0001144204-18-058784-index.html	Edgar Link	pending
0001144204-18-058784.txt	Edgar Link	pending
0001144204-18-058784-xbrl.zip	Edgar Link	pending
eltp-20180930.xml	Edgar Link	completed
eltp-20180930.xsd	Edgar Link	pending
eltp-20180930_cal.xml	Edgar Link	unprocessable
eltp-20180930_def.xml	Edgar Link	unprocessable
eltp-20180930_lab.xml	Edgar Link	unprocessable
eltp-20180930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv506444_10q.htm	Edgar Link	pending
tv506444_ex31-1.htm	Edgar Link	pending
tv506444_ex31-2.htm	Edgar Link	pending
tv506444_ex32-1.htm	Edgar Link	pending
tv506444_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2018 Q4 Form 10-Q Financial Statement

#000114420418058784 Filed on November 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2018 Q4 Form 10-Q Financial Statement

#000114420418058784 Filed on November 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp